Current Biomarkers of IgA Nephropathy

Area of Science:

• Nephrology
• Immunology
• Genetics

Background:

• IgA nephropathy (IgAN) is the most common primary glomerular disease, often leading to a poor prognosis and end-stage kidney disease (ESKD).
• Current diagnostic and prognostic tools, including kidney biopsy and clinical markers, lack the granularity needed for precise treatment decisions.
• Understanding the pathophysiology of IgAN, particularly the four-hit hypothesis, is crucial for identifying novel biomarkers.

Purpose of the Study:

• To review existing data on promising biomarkers for IgA nephropathy.
• To explore potential future biomarkers that could aid in early detection and treatment stratification.
• To provide an overview of novel diagnostic and prognostic markers beyond traditional methods.

Main Methods:

• Literature review of current research on IgA nephropathy biomarkers.
• Analysis of data on galactose-deficient IgA1 and its autoantibodies.
• Evaluation of emerging biomarkers including complement activation markers, microRNAs, genomic, and microbiome assays.

Main Results:

• Galactose-deficient IgA1 and its autoantibodies are key players in IgAN pathogenesis.
• Complement activation pathways represent a significant area for biomarker development in IgAN.
• MicroRNAs, genomic, and microbiome analyses offer nascent but promising avenues for future IgAN biomarker discovery.

Conclusions:

• Novel biomarkers are essential for improving the management of IgA nephropathy.
• Future research should focus on validating emerging biomarkers for clinical application in IgAN.
• Early identification of progressive IgAN patients through advanced biomarkers can guide timely therapeutic interventions.